CMS and private payers have reached a tipping point for uncontrolled inflation in cancer spend. In 2017, more oncologists than ever are saying bye-bye to “buy-and-bill” and hello to “value-based contracting”. In times where pharma’s fate is defined by a series of presidential tweets on drug prices, it is our commitment to value and outcomes that’s at the center of everyone’s attention.
Join three exclusive panelists for an expert roundtable to analyze how the US Oncology market might be upended by what has now become the new normal in single-payer systems in Europe. As we move beyond the process of care, our panelists will discuss oncology metrics pharma can develop in concert with all stakeholders – a discussion you don’t want to miss.
Sign-up for our free webinar to:
Vice President & Head, Health Economics & Outcomes Research, EMD SERONO
Principal, Altius Strategy Consulting
Partner, McGivney Global Advisors